Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$7.62 USD
+0.20 (2.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $7.62 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
VYGR 7.62 +0.20(2.70%)
Will VYGR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VYGR
Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?
Other News for VYGR
Commit To Purchase Voyager Therapeutics At $5, Earn 12.4% Annualized Using Options
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Optimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic Partnerships
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Voyager announces selection of development candidate for GBA1 Program